Table 2.
Sensitivity and specificity of the two assessed clinical screening checklists
| Measure | Checklist | ||
|---|---|---|---|
| By Ripperger et al. | By Postema et al. | In combination | |
| Checklist screening outcome, No. (%) | |||
| Not evaluateda | 1 (1.0) | 1 (1.0) | 1 (1.0) |
| Evaluated positive | 79 (77.5) | 66 (64.7) | 54 (52.9) |
| Evaluated negative | 22 (21.5) | 35 (34.3) | 10 (9.8) |
| Evaluation outcomeb, No. (%) | |||
| Checklist positive with pathogenic germline mutation | 10 (9.9) | 10 (9.9) | 10 (9.9) |
| Checklist positive without pathogenic germline mutation | 69 (68.3) | 56 (55.4) | 44 (43.6) |
| Checklist negative with pathogenic germline mutation | 0 | 0 | 0 |
| Checklist negative without pathogenic germline mutation | 22 (21.8) | 35 (34.7) | 47 (46.5) |
| Checklist assessment (%) | |||
| Sensitivity | 100 | 100 | 100 |
| Specificity | 24 | 38 | 52 |
aPatient excluded due to incomplete clinical data
bCalculation excluded patient not evaluated on checklist